Kevin Bielamowicz

3.3k total citations
30 papers, 684 citations indexed

About

Kevin Bielamowicz is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Kevin Bielamowicz has authored 30 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Kevin Bielamowicz's work include Glioma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (8 papers). Kevin Bielamowicz is often cited by papers focused on Glioma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (8 papers). Kevin Bielamowicz collaborates with scholars based in United States, Canada and Belgium. Kevin Bielamowicz's co-authors include Nabil Ahmed, Meenakshi Hegde, Analiz Rodriguez, Malini Mukherjee, Pavel Sumazin, Tiara T. Byrd, Kristen Fousek, Tsz‐Kwong Man, Meng-Fen Wu and Nikita Aware and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Kevin Bielamowicz

24 papers receiving 676 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Bielamowicz United States 12 471 203 200 167 160 30 684
Samuel Haile United States 10 559 1.2× 154 0.8× 366 1.8× 188 1.1× 202 1.3× 14 885
Selena Lorrey United States 9 373 0.8× 98 0.5× 320 1.6× 159 1.0× 230 1.4× 17 718
Khun Visith Keu United States 8 263 0.6× 130 0.6× 80 0.4× 35 0.2× 87 0.5× 18 458
Stephanie Mgebroff United States 12 1.4k 2.9× 334 1.6× 698 3.5× 43 0.3× 380 2.4× 24 1.7k
Shilpa Alekar United States 5 475 1.0× 44 0.2× 152 0.8× 63 0.4× 94 0.6× 5 655
Paris Kosti United Kingdom 7 395 0.8× 135 0.7× 232 1.2× 18 0.1× 185 1.2× 9 509
Mitchell Thorn United States 12 718 1.5× 220 1.1× 432 2.2× 11 0.1× 168 1.1× 17 975
Maria Ormhøj Denmark 7 231 0.5× 74 0.4× 97 0.5× 18 0.1× 124 0.8× 14 382
Claudia C. Bippes Germany 10 288 0.6× 82 0.4× 177 0.9× 16 0.1× 158 1.0× 13 453
Valentina S. Caputo United Kingdom 14 247 0.5× 79 0.4× 221 1.1× 36 0.2× 406 2.5× 31 822

Countries citing papers authored by Kevin Bielamowicz

Since Specialization
Citations

This map shows the geographic impact of Kevin Bielamowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Bielamowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Bielamowicz more than expected).

Fields of papers citing papers by Kevin Bielamowicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Bielamowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Bielamowicz. The network helps show where Kevin Bielamowicz may publish in the future.

Co-authorship network of co-authors of Kevin Bielamowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Bielamowicz. A scholar is included among the top collaborators of Kevin Bielamowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Bielamowicz. Kevin Bielamowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boklan, Jessica, Anne‐Marie Langevin, Kevin Bielamowicz, et al.. (2025). A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors. Cancers. 17(17). 2924–2924.
2.
3.
Moertel, Christopher L., Angela C. Hirbe, David Viskochil, et al.. (2024). ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).. Journal of Clinical Oncology. 42(16_suppl). 3016–3016. 6 indexed citations
4.
Elhusseiny, Abdelrahman M., et al.. (2024). Isolated eyelid neonatal Langerhans cell histiocytosis. Orbit. 44(1). 82–86. 2 indexed citations
5.
Bielamowicz, Kevin, et al.. (2024). Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse. Journal of Neuro-Oncology. 168(2). 367–373. 1 indexed citations
6.
Reed, Megan R., et al.. (2023). CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Current Oncology Reports. 25(5). 479–489. 98 indexed citations
7.
Sholler, Giselle L. Saulnier, Dan G. Duda, Genevieve Bergendahl, et al.. (2022). A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research. 28(18). 3950–3957. 11 indexed citations
8.
Laperrière, Normand, Vijay Ramaswamy, Éric Bouffet, et al.. (2021). Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study. Neuro-Oncology Advances. 3(1). 4 indexed citations
9.
Bielamowicz, Kevin, Rona Sonabend, Michael E. Scheurer, et al.. (2021). Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma. Journal of Neuro-Oncology. 155(1). 93–100. 27 indexed citations
10.
Sholler, Giselle L. Saulnier, Dan G. Duda, Genevieve Bergendahl, et al.. (2021). Abstract CT015: A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma, or alveolar rhabdomyosarcoma. Cancer Research. 81(13_Supplement). CT015–CT015. 1 indexed citations
11.
Gill, Pritmohinder S., Feliciano Yu, Patricia Porter‐Gill, et al.. (2021). Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital. Journal of Personalized Medicine. 11(5). 394–394. 14 indexed citations
12.
Patterson, John, et al.. (2020). CAR T Cell Therapy for Pediatric Brain Tumors. Frontiers in Oncology. 10. 1582–1582. 45 indexed citations
13.
Thakur, Satbir, Mohit Jain, A. J. Lewis, et al.. (2020). A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children. Blood. 136(Supplement 1). 25–25.
14.
15.
Donovan, Laura, Kevin Bielamowicz, Sujith K. Joseph, et al.. (2019). IMMU-05. COMBINATIONAL CAR T-CELL AND EPIGENETIC MODIFIER THERAPY TO TARGET POSTERIOR FOSSA TUMORS. Neuro-Oncology. 21(Supplement_2). ii93–ii94. 1 indexed citations
16.
Zhang, Chunfen, Satbir Thakur, Olena M. Vaske, et al.. (2019). Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia. Blood. 134(Supplement_1). 2633–2633.
17.
Bielamowicz, Kevin, Kristen Fousek, Tiara T. Byrd, et al.. (2017). Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro-Oncology. 20(4). 506–518. 339 indexed citations
18.
Hegde, Meenakshi, Zakaria Grada, Antonella Pignata, et al.. (2015). A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma. Journal for ImmunoTherapy of Cancer. 3(S2). 6 indexed citations
19.
Byrd, Tiara T., Kristen Fousek, Antonella Pignata, et al.. (2015). 720. Triple-Negative Breast Cancer Cells and Tumor Endothelium Are Killed by Targeting Tumor Endothelial Marker 8 (TEM8). Molecular Therapy. 23. S287–S288. 1 indexed citations
20.
Mukherjee, Malini, Tiara T. Byrd, Vita S. Brawley, et al.. (2014). Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme. Journal of Neuro-Oncology. 119(1). 27–35. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel Haile Breakdown of academic impact, for papers by Selena Lorrey Breakdown of academic impact, for papers by Khun Visith Keu Breakdown of academic impact, for papers by Stephanie Mgebroff Breakdown of academic impact, for papers by Shilpa Alekar Breakdown of academic impact, for papers by Paris Kosti Breakdown of academic impact, for papers by Mitchell Thorn Breakdown of academic impact, for papers by Maria Ormhøj Breakdown of academic impact, for papers by Claudia C. Bippes Breakdown of academic impact, for papers by Valentina S. Caputo
Rankless by CCL
2026